According to Hikma Pharmaceuticals
's latest financial reports the company has $0.27 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-12-31 | $0.27 B | -36.62% |
2021-12-31 | $0.42 B | 31.89% |
2020-12-31 | $0.32 B | -26.92% |
2019-12-31 | $0.44 B | 48.82% |
2018-12-31 | $0.29 B | 30.84% |
2017-12-31 | $0.22 B | 46.45% |
2016-12-31 | $0.15 B | -71.97% |
2015-12-31 | $0.55 B | 97.5% |
2014-12-31 | $0.28 B | 66.67% |
2013-12-31 | $0.16 B | -4.82% |
2012-12-31 | $0.17 B | 81.39% |
2011-12-31 | $97.31 M | 46.79% |
2010-12-31 | $66.29 M | -2.51% |
2009-12-31 | $67.99 M | 7% |
2008-12-31 | $63.54 M | 84.02% |
2007-12-31 | $34.53 M | -62.29% |
2006-12-31 | $91.56 M | -35.1% |
2005-12-31 | $0.14 B | 187.29% |
2004-12-31 | $49.1 M | 123% |
2003-12-31 | $22.02 M | 82.07% |
2002-12-31 | $12.09 M |